These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 15901984)

  • 21. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients.
    Lehmkuhl HB; Arizon J; Viganò M; Almenar L; Gerosa G; Maccherini M; Varnous S; Musumeci F; Hexham JM; Mange KC; Livi U;
    Transplantation; 2009 Jul; 88(1):115-22. PubMed ID: 19584690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
    Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis.
    Ciancio G; Burke GW; Gaynor JJ; Ruiz P; Roth D; Kupin W; Rosen A; Miller J
    Transplantation; 2006 Mar; 81(6):845-52. PubMed ID: 16570006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of sirolimus, mycophenolate mofetil, cyclosporine, azathioprine, and steroids on wound healing in 513 kidney-transplant recipients.
    Flechner SM; Zhou L; Derweesh I; Mastroianni B; Savas K; Goldfarb D; Modlin CS; Krishnamurthi V; Novick A
    Transplantation; 2003 Dec; 76(12):1729-34. PubMed ID: 14688524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury.
    Ruggenenti P; Perico N; Gotti E; Cravedi P; D'Agati V; Gagliardini E; Abbate M; Gaspari F; Cattaneo D; Noris M; Casiraghi F; Todeschini M; Cugini D; Conti S; Remuzzi G
    Transplantation; 2007 Oct; 84(8):956-64. PubMed ID: 17989600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Steroid withdrawal and reduction of cyclosporine A under mycophenolate mofetil after heart transplantation.
    Faulhaber M; Mäding I; Malehsa D; Raggi MC; Haverich A; Bara CL
    Int Immunopharmacol; 2013 Apr; 15(4):712-7. PubMed ID: 23454241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
    Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
    Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eight-year outcomes of 'the Cairo Kidney Centre sequential protocol'.
    Fayad T; William E; Tawfik N; Habashy B; Abou-Youssef HS; Shokry S; Khalil S; Morsy A; Barsoum R
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():23-9. PubMed ID: 25894123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study.
    Lebranchu Y; Thierry A; Toupance O; Westeel PF; Etienne I; Thervet E; Moulin B; Frouget T; Le Meur Y; Glotz D; Heng AE; Onno C; Buchler M; Girardot-Seguin S; Hurault de Ligny B
    Am J Transplant; 2009 May; 9(5):1115-23. PubMed ID: 19422337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids.
    Offner G; Toenshoff B; Höcker B; Krauss M; Bulla M; Cochat P; Fehrenbach H; Fischer W; Foulard M; Hoppe B; Hoyer PF; Jungraithmayr TC; Klaus G; Latta K; Leichter H; Mihatsch MJ; Misselwitz J; Montoya C; Müller-Wiefel DE; Neuhaus TJ; Pape L; Querfeld U; Plank C; Schwarke D; Wygoda S; Zimmerhackl LB
    Transplantation; 2008 Nov; 86(9):1241-8. PubMed ID: 19005406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months.
    Gonwa T; Mendez R; Yang HC; Weinstein S; Jensik S; Steinberg S;
    Transplantation; 2003 Apr; 75(8):1213-20. PubMed ID: 12717205
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy.
    Weir MR; Ward MT; Blahut SA; Klassen DK; Cangro CB; Bartlett ST; Fink JC
    Kidney Int; 2001 Apr; 59(4):1567-73. PubMed ID: 11260422
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group.
    Kahan BD
    Lancet; 2000 Jul; 356(9225):194-202. PubMed ID: 10963197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
    Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
    Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Initial experience with sirolimus and mycophenolate mofetil for renal rescue from cyclosporine nephrotoxicity after heart transplantation.
    Lyster H; Panicker G; Leaver N; Banner NR
    Transplant Proc; 2004 Dec; 36(10):3167-70. PubMed ID: 15686720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial.
    Guba M; Pratschke J; Hugo C; Krämer BK; Nohr-Westphal C; Brockmann J; Andrassy J; Reinke P; Pressmar K; Hakenberg O; Fischereder M; Pascher A; Illner WD; Banas B; Jauch KW;
    Transplantation; 2010 Jul; 90(2):175-83. PubMed ID: 20463641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimizing the immunosuppressive regimen in heart transplantation.
    Eisen H; Ross H
    J Heart Lung Transplant; 2004 May; 23(5 Suppl):S207-13. PubMed ID: 15093807
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A.
    Abou-Ayache R; Büchler M; Lepogamp P; Westeel PF; Le Meur Y; Etienne I; Lobbedez T; Toupance O; Caillard S; Goujon JM; Bergougnoux L; Touchard G
    Nephrol Dial Transplant; 2008 Jun; 23(6):2024-32. PubMed ID: 18199693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study.
    Oberbauer R; Kreis H; Johnson RW; Mota A; Claesson K; Ruiz JC; Wilczek H; Jamieson N; Henriques AC; Paczek L; Chapman J; Burke JT;
    Transplantation; 2003 Jul; 76(2):364-70. PubMed ID: 12883194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.